Moomoo AI 已提取核心信息
On January 23, 2024, Johnson & Johnson reported its financial results for the fourth quarter and the full year ended December 31, 2023. The company announced a 7.3% increase in fourth-quarter sales, reaching $21.4 billion, with an operational growth of 7.2% and an adjusted operational growth of 5.7%. Excluding the COVID-19 vaccine, the operational growth was 10.9%. Fourth-quarter earnings per share (EPS) rose by 39.3% to $1.70, and adjusted EPS increased by 11.7% to $2.29. For the full year, Johnson & Johnson saw a 6.5% increase in sales to $85.2 billion, with operational growth of 7.4% and adjusted operational growth of 5.9%. The full-year EPS decreased by 15.3% to $5.20 due to a special one-time charge in the first quarter, while the adjusted EPS grew by 11.1% to $9.92. The company confirmed its 2024 guidance, projecting operational sales growth of 5.0% - 6.0% and an adjusted operational EPS of $10.55 - $10.75, indicating a mid-point growth of 7.4%. Joaquin Duato, Chairman and CEO, expressed confidence in the company's ability to lead health innovation. The report also highlighted regulatory approvals, product launches, and research advancements in various healthcare segments.
On January 23, 2024, Johnson & Johnson reported its financial results for the fourth quarter and the full year ended December 31, 2023. The company announced a 7.3% increase in fourth-quarter sales, reaching $21.4 billion, with an operational growth of 7.2% and an adjusted operational growth of 5.7%. Excluding the COVID-19 vaccine, the operational growth was 10.9%. Fourth-quarter earnings per share (EPS) rose by 39.3% to $1.70, and adjusted EPS increased by 11.7% to $2.29. For the full year, Johnson & Johnson saw a 6.5% increase in sales to $85.2 billion, with operational growth of 7.4% and adjusted operational growth of 5.9%. The full-year EPS decreased by 15.3% to $5.20 due to a special one-time charge in the first quarter, while the adjusted EPS grew by 11.1% to $9.92. The company confirmed its 2024 guidance, projecting operational sales growth of 5.0% - 6.0% and an adjusted operational EPS of $10.55 - $10.75, indicating a mid-point growth of 7.4%. Joaquin Duato, Chairman and CEO, expressed confidence in the company's ability to lead health innovation. The report also highlighted regulatory approvals, product launches, and research advancements in various healthcare segments.
2024年1月23日，强生公司公布了截至2023年12月31日的第四季度和全年财务业绩。该公司宣布第四季度销售额增长7.3％，达到214亿美元，运营增长7.2％，调整后的运营增长5.7％。不包括 COVID-19 疫苗，业务增长为10.9％。第四季度每股收益（EPS）增长了39.3％，至1.70美元，调整后的每股收益增长了11.7％，至2.29美元。全年强生公司的销售额增长了6.5％，达到852亿美元，运营增长了7.4％，调整后的运营增长了5.9％。由于第一季度的一次性特别收费，全年每股收益下降了15.3％，至5.20美元，而调整后的每股收益增长了11.1％，至9.92美元。该公司确认了其2024年的预期，预计营业销售额增长5.0％至6.0％，调整后的营业每股收益为10.55美元至10.75美元，表明中点增长7.4％。董事长兼首席执行官华金·杜阿托对公司领导健康创新的能力表示信心。该报告还重点介绍了各个医疗领域的监管批准、产品发布和研究进展。
2024年1月23日，强生公司公布了截至2023年12月31日的第四季度和全年财务业绩。该公司宣布第四季度销售额增长7.3％，达到214亿美元，运营增长7.2％，调整后的运营增长5.7％。不包括 COVID-19 疫苗，业务增长为10.9％。第四季度每股收益（EPS）增长了39.3％，至1.70美元，调整后的每股收益增长了11.7％，至2.29美元。全年强生公司的销售额增长了6.5％，达到852亿美元，运营增长了7.4％，调整后的运营增长了5.9％。由于第一季度的一次性特别收费，全年每股收益下降了15.3％，至5.20美元，而调整后的每股收益增长了11.1％，至9.92美元。该公司确认了其2024年的预期，预计营业销售额增长5.0％至6.0％，调整后的营业每股收益为10.55美元至10.75美元，表明中点增长7.4％。董事长兼首席执行官华金·杜阿托对公司领导健康创新的能力表示信心。该报告还重点介绍了各个医疗领域的监管批准、产品发布和研究进展。
有用
没用